QPS Delaware expands translational medicine capabilities
Wednesday, August 9, 2017
QPS Holdings, a full-service GLP/GCP-compliant CRO providing testing services to support preclinical and clinical research and development, is investing in additional technical personnel and laboratory capacity for translational medicine at its flagship Delaware Technology Park facility. This significant expansion will enable QPS Delaware to process the high sample volumes required for phase III clinical drug trials.
Once complete, new hiring is projected to increase laboratory staff from 57 to 88. Most of these additions are to be technical personnel and will raise the number of analysis teams from seven to eleven. The relationship-building, one-client-one-team approach is a hallmark of QPS efficiency. A special working group to handle regulatory authorities’ rising demand for neutralizing antibody assays has also been added.
To accommodate the increase in technical operations, QPS has expanded the square footage devoted to immunobioanalysis and cell culture, as well as the protein mass spectrometry area.
“For a long time, clients have known us as the boutique CRO—a high quality outfit that can stabilize difficult assays in the initial stages of clinical investigation,” said John L. Kolman, Ph.D., VP and Global Head of Translational Medicine at QPS. “Now we are in a position to follow through and support phase III, even for very large studies.”
Translational Medicine is a growing, multi-disciplinary science focused on speeding translation of experimental discoveries into effective diagnostic tools and therapies.